Prevention and treatment of osteoporosis in women

Abstract

The British Menopause Society Council aims to aid health professionals to inform and advise women about post reproductive health. Osteoporosis affects one in three women. This guidance regarding estrogen and non-estrogen-based treatments for osteoporosis responds to the controversies about the benefits and risks of individual agents. Treatment choice should be based on up-to-date evidence-based information and targeted to individual women’s needs.

Keywords

Bisphosphonates calcium and vitamin D denosumab HRT SERMs PTH

Introduction

Osteoporosis is very much a disease of older women affecting one in three women compared to one in five men. Osteoporosis is as a skeletal disorder characterized by compromised bone strength predisposing to an increased risk of fracture. Fractures of the wrist, hip and vertebrae, which are the main clinical manifestations of osteoporosis, have enormous impact on quality of life, result in significant economic burden and are associated with considerable excess mortality. The annual number of hip fractures in the UK due to osteoporosis is expected to rise by 44% from 70,000 in 2006 to 101,000 by 2020.¹ Pharmacological and non-pharmacological therapies will be examined (Table 1).

Table 1.

Interventions for the prevention and treatment of osteoporosis.

Hormone replacement therapy• estrogen alone• estrogen plus progestogen

Bisphosphonates• alendronate• risedronate• ibandronate• zoledronate

Denosumab

Raloxifene

Parathyroid hormone peptides

Calcium and vitamin D

Exercise

Pharmacological interventions

All pharmacological interventions except for parathyroid hormone act mainly by inhibiting bone resorption. Very few data exist about long-term efficacy for reducing fractures (i.e. more than 10 years of treatment) and about the safety of combinations of therapy. In many of the controlled studies, the placebo group received calcium and vitamin D supplements.

Hormone replacement therapy

There is evidence from randomized controlled trials including the Women’s Health Initiative (WHI) that hormone replacement therapy (HRT) reduces the risk of both spine and hip and other osteoporotic fractures even in women at low risk² as well as in those with established osteoporosis.³ The ‘standard’ bone conserving doses of estrogen were considered to be oral estradiol 2 mg, conjugated equine estrogens 0.625 mg and transdermal 50 mcg patch. However, it is now evident that lower doses also conserve bone mass.⁴ Epidemiological studies have suggested that for HRT to be an effective method of preventing fracture continuous and lifelong use is required. However, it has been shown that just a few years treatment with HRT around the time of menopause may have a long term effect on fracture reduction.⁵ European regulatory authorities (December 2003) advised that HRT should not be used as a first-line treatment for osteoporosis prevention as the risks outweigh the benefits.⁶ This view was robustly challenged,⁷ but astonishingly, despite a subsequent wealth of further evidence, the regulatory authorities have not revised their position. Yet, HRT is an effective safe and cheap treatment. Whilst alternatives are available for the treatment of osteoporosis in elderly women, estrogen still remains the best and safest option for prevention, particularly in younger (aged less than 60 years) and/or symptomatic women. The initiation of HRT for fracture prevention in women over 60 needs the starting dose to be tailored to the age of the woman.⁸

Estrogen remains the treatment of choice in women with premature ovarian failure.⁹ No clinical trial evidence attests the efficacy or safety of the use of non-estrogen-based treatments, such as bisphosphonates, densosumab or raloxifene, in these women.

Although some women will be happy to take HRT for life, others may view treatment as a continuum of options and may wish to change to other agents such as a bisphosphonate, because of the possible small increase in risk of diagnosis (but not mortality) of breast cancer associated with the long-term use of combined HRT.

Bisphosphonates

Bisphosphonates are chemical analogues of naturally occurring pyrophosphates, thus allowing them to be integrated into bone where they have a direct effect on osteoclasts, thereby reducing bone resorption. This makes metabolism an extremely slow process, indeed the skeletal half-life of alendronate has been estimated as high as over 12 years. There are concerns about effects on the fetal skeleton and bisphosphonates are not advised in women with fertility aspirations. However, they are widely used for osteoporosis and are effective in fracture prevention.¹⁰

Alendronate, risedronate, ibandronate and zoledronate are all used in the treatment of postmenopausal osteoporosis, and are also used in corticosteroid-induced osteoporosis.

The question of how long to prescribe a bisphosphonate has not been fully clarified yet. There are concerns about fatigue damage due to oversuppression of bone remodelling with long-term use in some individuals leading to femoral fragility fractures and also development of osteonecrosis in the jaw.¹¹ Although such adverse effects are very rare (around 1 in 5000 women per year), five years of treatment with a one- to two-year ‘holiday’ have been proposed to try to reduce these risks.¹¹ This may not be applicable in glucocorticoid-induced osteoporosis. Because of the very long skeletal retention time of bisphosphonates, any very long-term adverse effects still remain unknown. They should therefore be avoided where possible in younger (e.g. aged <65 years) patients.

The vast majority of reports of osteonecrosis of the jaw refer mainly to intravenous bisphosphonates used in the oncological setting. Very few cases have been reported in women using oral bisphosphonates for osteoporosis. These cases usually, but not exclusively, follow dental extractions, and dental review could be considered in women with significant dental disease before the initiation of bisphosphonates therapy.

Fragility fractures of the femoral shaft have now been increasingly reported in patients on long-term bisphosphates. These occur spontaneously but may be preceded by thigh pain and the presence of cortical ‘beaking’ on plain radiographs of the femur.¹²

Alendronate

Alendronate reduces vertebral and non-vertebral fractures by 50% in randomized controlled trials in osteoporotic women.¹³ The dose for osteoporosis treatment is 70 mg once weekly.

Risedronate

Risedronate reduces vertebral and non-vertebral fractures in randomized controlled trials.¹⁴ The dose for treatment of established disease is 35 mg once weekly.

Ibandronate

Ibandronate has been shown to reduce the incidence of vertebral, but not non-vertebral, fractures, by 50% in randomized controlled trials undertaken in postmenopausal women.¹⁵ The dose is 150 mg orally once a month, or 3 mg by intravenous injection every three months.

Zoledronate

Zoledronate has been shown to reduce both spine and hip fracture incidence in elderly osteoporotics.¹⁶ It is given in a dose of 60 mg as an annual intravenous infusion. It is the most potent of the currently used bisphosphonates and hence has the highest rate of adverse effects, which can also include atrial fibrillation and inflammatory eye disease.

Denosumab

Denosumab is a monoclonal antibody to receptor activator of nuclear factor κ-B ligand (RANK-L), a major signal promoting osteoclast activity. It is as effective as the bisphosphonates in terms of spine and hip fracture reduction in osteoporotic women,¹⁷ but also has similar adverse effects in terms of osteonecrosis of the jaw and femoral fragility fractures. However, it is not retained in the skeleton and may be a safer option for younger women. Because RANK-L also has a role in the immune system, denosumab is associated with an increased risk of infections and should be avoided in patients with increased susceptibility. There is evidence of an accelerated loss of bone on discontinuation of denosumab and hence a concern about an increased risk of fractures.¹⁸ It may be prudent to introduce another treatment when discontinuing denosumab.

Selective estradiol receptor modulators

These compounds possess estrogenic actions in certain tissues and anti-estrogenic actions in others. Raloxifene is licensed for the prevention of osteoporosis-related vertebral fracture. It reduces vertebral but not non-vertebral fracture by around 35%.¹⁹ The dose is 60 mg/day. It also reduces the risk of breast cancer to the same extent as tamoxifen.²⁰ Side-effects include hot flushes and calf cramps. It was thought that it could be cardioprotective from its effects on lipids, and the Raloxifene Use for the Heart (RUTH) study found that it did reduce the risk of coronary heart disease in those initiating treatment below age 60 years, but it increased the risk of fatal stroke and venous thromboembolism.¹⁹

Parathyroid hormone peptides

Recombinant 1-34 parathyroid hormone (teriparatide), given as a subcutaneous daily injection of 20 µg, reduces vertebral and non-vertebral fractures in postmenopausal women with osteoporosis.²¹ It has been shown to reduce the risk of vertebral and non-vertebral, but not hip, fractures. Because it costs considerably more than other options, it is reserved for patients with severe osteoporosis who are unable to tolerate, or seem to be unresponsive to, other treatments.

Non-pharmacological interventions

Calcium and vitamin D

Provision of adequate dietary or supplemental calcium and vitamin D can be a part of osteoporosis management. The effects of calcium and vitamin D supplements alone or in combination on fracture, however, are contradictory and may depend on the study population.^22,23 Hip fracture reduction has been shown in elderly women in residential care, but such women may be more frail, have lower dietary intakes of calcium and vitamin D and are at higher risk of fracture than those living in the community in whom fracture reduction has not been shown.

Furthermore, the Women’s Health Initiative Study showed an increase in kidney stones in low-risk women taking calcium and vitamin D supplements.²⁴ and there are controversial claims about increased cardiovascular risk being associated with such supplements.

Exercise

Although certain exercise regimens may increase bone density, a role for exercise in preventing osteoporotic fractures has not been convincingly shown.^25,26 Exercise regimens can be helpful in the management of established osteoporosis. The benefits are mainly related to increased wellbeing, muscle strength, postural stability and a reduction of chronic pain rather than an increase of skeletal mass. Exercise has to be structured carefully, because of concerns about falls and fractures.

Summary practice points

HRT reduces the risk of both spine and hip as well as other osteoporotic fractures.

Estrogen remains the treatment of choice for osteoporosis prevention in menopausal women, and especially in those with premature ovarian insufficiency.

Bisphosphonates are effective for treatment of established osteoporosis, reducing both spine and hip fractures.

Bisphosphonates have a very long skeletal retention time and hence should be used with caution in younger postmenopausal women (e.g. those aged below 65 years).

Denosumab is an effective treatment for reducing spine and hip fractures in osteoporotic women.

Denosumab should be avoided in women with increased susceptibility to infections.

There may be an increased risk of fractures after denosumab discontinuation.

Provision of adequate dietary or supplemental calcium and vitamin D is a part of osteoporosis management.

However, the effects of calcium and vitamin D supplements alone on fracture reduction are contradictory and may depend on the study population.

Footnotes

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

References

National Institute for Health and Care Excellence. Osteoporosis: assessing the risk of clinical fracture: Clinical Guideline (CG146). August 2012.

Manson

Chlebowski

Stefanick

et al . Menopausal hormone therapy and health outcomes during the interventions and postintervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013; 310: 1353–1368.

Lufkin

Wahner

O'Fallon

et al . Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Int Med 1992; 117: 1–9.

Lees

B and

Stevenson

JC.

The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17β and dydrogesterone.

Osteoporous Int 2001; 12: 251–258.

Bagger

Tankó

Alexandersen

et al . Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 2004; 34: 728–735.

Committee on Safety of Medicines. Further advice on safety of HRT: risk: benefit unfavourable for first-line use in prevention of osteoporosis. CEM/CMO/2003/19. www.mhra.gov.uk.

Stevenson

on behalf of the International Consensus Group on HRT and Regulatory Issues. HRT, osteoporosis and regulatory authorities Quis custodiet ipsos custodes? Hum Reprod 2006; 21: 1668–1671.

Lobo

Pickar

Stevenson

et al . Back to the future: hormone replacement therapy as part of a prevention strategy for women at the onset of menopause. Atherosclerosis 2016; 254: 282–290.

Panay

Hamoda

Arya

et al . The 2013 British Menopause Society & Women’s Health Concern recommendations on hormone replacement therapy. Menopause Int 2013; 19: 59–68

10.

Jansen

Bergman

Huels

et al . The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. Semin Arthritis Rheum 2011; 40: 275–284.

11.

Anagnostis

PG and

Stevenson

JC.

Bisphosphonate drug holidays - when, why and for how long?

Climacteric 2015; 18: 32–38.

12.

Shane

Burr

Ebeling

et al . Atypical subtrochanteric and diaphyseal femoral fractures: a second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014; 29: 1–23.

13.

Black

Schwartz

Ensrud

et al ; FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296: 2927–2938.

14.

Silverman

Watts

Delmas

et al . Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporosis Int 2007; 18: 25–34.

15.

Di Munno

Seddie

AD.

Efficacy of ibandronate: a long term confirmation.

Clin Cases Miner Bone Metab 2010; 7: 23–26.

16.

Black

Reid

Cauley

et al . The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2015; 30: 934–944.

17.

Cummings

San Martin

McClung

et al . Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756–765.

18.

Tsourdi

Langdahl

Cohen-Solal

et al . Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 2017; 105: 11–17.

19.

Barrett-Connor

Mosca

Collins

et al.

Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.

N Engl J Med 2006; 355: 125–137.

20.

Vogel

Costantino

Wickerham

et al . National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006; 295: 2727–2741.

21.

Neer

Arnaud

Zanchetta

et al . Effect of parathyroid hormone on vertebral bone mass and fracture incidence among postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434–1441.

22.

Zhao

J-G

Zeng

X-T

Wang

et al . Association between calcium or vitamin D supplementation and fracture incidence in community-dwelling older adults. A systematic review and meta-analysis. JAMA 2017; 318: 2466–2482.

23.

Cano

Chedraui

Goulis

et al . Calcium in the prevention of postmenopausal osteoporosis: EMAS clinical guide. Maturitas 2018; 107: 7–12.

24.

Jackson

LaCroix

Gass

et al . Women’s Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006; 354: 669–683.

25.

Howe

Shea

Dawson

et al.

Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev 2011; 7: CD000333.

26.

Silva

Eslick

GD and

Duque

Exercise for falls and fracture prevention in long term care facilities: a systematic review and meta-analysis.

JAMDA 2013; 14: 685–689.